- Company
- Whether companies give up developing COVID-19 vaccines
- by Kim, Jin-Gu Mar 16, 2022 05:57am
- Domestic pharmaceutical companies are divided over the development of the COVID-19 vaccine. After the introduction of Pfizer, Moderna Vaccine, some companies stopped developing due to reduced commerciality and difficulties in recruiting clinical participants. Companies that are newly developing in preparation of the coronavirus are steadily
- Policy
- HPV vaccine, which costs 600,000 won, free of charge ?
- by Lee, Jeong-Hwan Mar 16, 2022 05:57am
- Human papilloma virus (HPV) vaccine, which costs about 200,000 won per inoculation and 600,000 won per inoculation, is expected to do well in the health insurance coverage of room 9. It is the gate that President-elect Yoon Seok-yeol promised to expand the insurance of Gadasil 9 as a life-friendly pledge. Looking at the 13th "59-second sho
- Company
- Exon 20 insertion targeting Exkivity comes to Korea
- by Eo, Yun-Ho Mar 15, 2022 05:58am
- Takeda’s new lung cancer drug ‘Exkivity’ is coming to Korea. According to industry sources, Takeda Pharmaceuticals Korea recently submitted an application for the marketing authorization of ‘Exkivity (mobocertinib).’ The drug is expected to be approved within the year at the earliest. Exkivity was approved in the US in September
- Policy
- The government will begin to establish an Asian vaccine fund
- by Lee, Jeong-Hwan Mar 15, 2022 05:58am
- The government will review the need for joint vaccine purchase funds in Asia and start working on creating grounds for establishment. The move is aimed at preventing repeated cases of global difficulties in supplying vaccines with COVID-19 Pandemic and bridging the gap in accessibility to public vaccines and biopharmaceuticals by country.
- Company
- Samsung·Celltrion speeds up dev of follow-on similars
- by Ji Yong Jun Mar 15, 2022 05:58am
- Celltrion and Samsung Bioepis’s follow-on biosimilars are gaining momentum in the global market. A total of 11 biosimilars from the two companies are being prepared for their launch into the global market. According to the industry on the 14th, Celltrion’s Avastin biosimilar is awaiting approval in the US and European market this year.
- Policy
- RET mutant target anticancer drug has been approved
- by Lee, Tak-Sun Mar 15, 2022 05:57am
- For the first time in Korea, a new anticancer drug targeting a REarranged during Transfection (RET) mutation has been approved. RET is a phosphorylation enzyme that can cause cancer and is known to promote the proliferation of cancer cells when mutated or combined with other genes. The MFDS approved "Retevmo Capsule 40·80mg (Selpercatinib
- Policy
- Yoon Seok-yeol was elected president
- by Lee, Jeong-Hwan Mar 15, 2022 05:57am
- Attention is focusing on the pledge to establish a global vaccine hub and quickly register health insurance for severe treatments. In the 20th presidential election, Yoon Seok-yeol, the power of the people, was confirmed to win the election, beating Lee Jae-myung of the Democratic Party of Korea. Candidate Yoon Seok-yeol won 48.56% (16,394,81
- Policy
- Yoon Seok-yeol expands R&D for telemedicine & bio
- by Lee, Jeong-Hwan Mar 14, 2022 05:51am
- After the inauguration of the Yoon Seok-yeol administration, legal experts analyzed that the biohealth industry policy paradigm will shift, such as expanding digital healthcare and strengthening government R&D support in advanced medical fields of vaccines and treatments. It is predicted that the biohealth sector will be transformed compar
- Policy
- P3T for Sarepta’s DMD treatment approved in Korea
- by Lee, Hye-Kyung Mar 14, 2022 05:51am
- A Phase III trial for the Duchenne muscular dystrophy treatment 'SRP-4045(casimersen)’ and 'SRP-4053 (golodirsen)' will be conducted in Korea. The Ministry of Food and Drug Safety has recently approved Ppdd Velllovement Pte Ltd’s application for the double-blind, placebo-controlled, multicenter clinical trial to evaluate Sarepta Therap
- Company
- Pharma·Biopharmas make or break COVID-19 CMO deals
- by Ji Yong Jun Mar 14, 2022 05:51am
- Domestic pharmaceutical companies are experiencing mixed results regarding their CMO businesses for COVID-19 vaccines. Samsung Biologics and SK Bioscience are already in the process of manufacturing COVID-19 vaccines. On the other hand, GC Pharma and Huons Global gave up their COVID-19 vaccine CMO business. In addition, uncertainties continu
